NASDAQ:NAMS 11 October 2025

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma shares fell about 5% to $33.42 in afternoon trading Monday after two insiders filed Form 144 notices for proposed stock sales tied to RSU vesting. CFO M. Ian Somaiya and CSO Johannes Kastelein flagged plans to sell a combined 11,118 shares. The stock touched an intraday low of $32.68. Biotech stocks broadly lagged the market ahead of Friday’s U.S. jobs report.

5 January 2026

NASDAQ:NAMS·Stock Market

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma shares jumped 12.3% to $37.05 on Oct. 10, 2025, hitting a new 52-week high and valuing the company at $4.2 billion. Its lead drug, obicetrapib, showed a 21% drop in major cardiovascular events and lowered Alzheimer’s biomarkers in Phase 3 trials. The EMA is reviewing marketing applications; a key U.S. trial will read out in 2026. The firm ended Q2 with $783.3 million in cash.

11 October 2025

NASDAQ:NAMS

Kennametal (KMT) Valuation Examined After Recent Share Price Decline
March 20, 2026, 3:19 AM EDT. Kennametal (KMT) shares fell about 9% last week and 10% over the month following a strong 22% gain in three months. Despite a 67.9% total shareholder return over one year, recent pullbacks raise questions on future growth prospects. The stock trades slightly below analyst targets but well below some intrinsic value estimates, with a fair value around $37.13 versus a $35.18 close. Cost-cutting efforts, including $125 million in expected savings by fiscal 2028, aim to improve margins. However, risks include persistent weak demand and potential delay in realizing efficiencies. Investors should weigh these factors carefully amid mixed market signals and consider alternative industrial exposure opportunities.